Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Medical Center Groningen
About this trial
In this feasibility study, bronchoscopy will be combined with fluorescence molecular imaging using the near-infrared fluorescence (NIRF) tracer bevacizumab-800CW for assessment of pulmonary lesions and/or lymph nodes considered to be malignant.
Eligibility criteria
Qualifiers
Signed informed consent prior to participation in the study.
Age ≥ 18 years.
Patient has at least one intrabronchial, near-to-airway located or peripheral pulmonary nodule - with or without pathological lymph nodes - which is considered malignant (independent of its primary origin).
Patient is considered fit to undergo a diagnostic and/or therapeutic bronchoscopy (with or without addition of virtual navigation and/or endobronchial ultrasound; including propofol sedation or general anesthesia if either is indicated) to obtain tumor material according to standard care protocols.
Disqualifiers
History of infusion reactions to bevacizumab.
Medical or psychiatric conditions that compromise the patient's ability to give informed consent.
Pregnancy or breast feeding.
Trial design
Treatments tested in this trial
- injection with 15 mg bevacizumab-800CW before bronchoscopy
- injection with 25 mg bevacizumab-800CW before bronchoscopy
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov